However, about 15–20% of all breast cancer cases, classified as triple negative breast cancers (TNBCs), lack expression of these three molecules, thereby precluding the use of endocrine or anti-HER2 targeted therapies. The gene discussed is ERBB2; the disease is breast carcinoma.